Photo
Topics • Strategy

Sustainability – The Many Facets of Action

Climate change, energy crisis, the call for a more environmentally compatible production method and socially responsible action do not stop at the pharmaceutical and biotech industries. Sustainability is becoming a central competitive and reputation factor and carries a high economic value. This need not be to the industry´s disadvantage. It helps companies to make processes more efficient, reduces energy consumption and keeps costs in check. But is the pharmaceutical industry already doing enough in this regard?

Photo
Topics • Strategy

Siegfried Demonstrates Biologics Expertise in Hameln

The Fill & Finish of biologic drugs is expensive and poses special technological challenges for CDMOs. At the German site in Hameln, Siegfried has successfully proven these capabilities over the past two years by producing Covid-19 vaccines and a significant number of clinical batches for several biological companies. By investing in its competencies, capacities and flexibility, the company intends to further expand this demanding but promising business area.

Photo
Topics • Strategy

"We Want to Be a Big Fish"

The CDMO (contract development and manufacturing organizations) business has a bright future, of that Siegfried CEO Wolfgang Wienand is certain. The economic advantages alone speak for this compared to in-house production by the pharmaceutical companies themselves. Although Siegfried has already reached sufficient critical size within its industry, he sees the company continuing on its growth path. The goal is to take over an even larger share of the value chain from pharmaceutical companies in the future.

Photo
Topics • Strategy

A Flexible Chemical Business Model

Actylis, leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, made its debut in September 2022. The new CDMO was created from US-based fine and specialty chemicals distributor Aceto. Gilles Cottier, CEO of Actylis, has played a tremendous role in Aceto’s transformation into the new Actylis brand. Ralf Kempf and Michael Reubold asked Cottier about the reasons for creating the new brand identity, the challenges of combining so many companies, and Actylis' strategy going forward.

Photo
Topics • Technology

PARTEC 2023: Call for Papers

The 2023 edition of PARTEC, the International Congress on Particle Technology, will take place on September 26−28, 2023 in Nuremberg, Germany. As one of the world's major scientific congresses for particle and bulk solids technology, it provides an international forum for R&D in new technologies.

Photo
Topics • Technology

AI Maturity Model for GxP Application

Artificial intelligence (AI) has become one of the supporting pillars for digitalization in many areas of the business world. The pharmaceutical industry and its GxP-regulated areas also want to use AI in a beneficial way, but only a small fraction of companies follows a systematic approach for the digitalization of their operations and validation. However, the assurance of integrity and quality of outputs via computerized system validation is essential for applications in GxP environments.

Photo
Topics • Strategy

Sustainability and the Chemicals Industry

The chemicals industry is one of the world’s largest industrial sectors, worth €3,471 billion in 2020. It includes producers of industrial chemicals, polymers, pesticides, food and feed additives, and cosmetics, and is growing rapidly. By some estimates it will reach almost $22,000 billion by 2060.

Photo
Topics • Innovation

Expert Statement: Kai Rossen, Euroapi

Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.

Photo
Topics • Strategy

The Japanese Pharma Market

Japan continues to be one of the largest pharmaceutical markets in the world, making up approximately 7% of the global share. Historically, Japan has been viewed as insular compared to other developed markets such as Europe or the US, with foreign companies reporting high barriers to entry.

Photo
Topics • Strategy

Overall Equipment Effectiveness (OEE)

The primary goal for any manufacturing or process organization is to produce a profit and return on net asset (RONA) to shareholders and other stakeholders. Safety and environmental performance are secondary goals – not secondary in importance, but no manufacturing plant was ever built with the sole and explicit purpose of being safe and environmentally responsible.

Photo
Topics • Chemistry

Proactive Supplier Risk Mitigation for Manufacturing and Testing Organizations

There is a new urgency in the market for manufacturers and testing organizations to be prepared for rapid, unexpected changes in material resource access, exacerbated by turbulent regional and global events. This focus is in addition to reinforcing routine risk mitigation activities around the raw material supply chain, adding to the relevance and impact of the topic.

1812 more articles

Top-Feature

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing